It would be very interesting to follow patients with low-grade tumours at diagnosis in a randomised clinical trial setting with Bax, Bcl-2, CD40 and CD40L mapping and note whether overexpression or underexpression of these markers by immunohistochemistry predates the aggressive clinical behaviour and therefore indicates a point of therapeutic intervention. This evidence concerns the gene BCL2 and neoplasm.